Navigation Links
Surveyed U.S. and European Neurologists Agree that a Therapy's Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
Date:3/20/2013

BURLINGTON, Mass., March 20, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European neurologists agree that a therapy's effect on physical disability is the most influential attribute when making prescribing decisions for secondary-progressive multiple sclerosis (SP-MS)*. These same neurologists cite a therapy's effect on quality of life as the second-most important attribute, ahead of an effect on relapses, imaging metrics and other functional domains.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

Current management of SP-MS relies on the use of mainline disease-modifying therapies (which include interferon-betas and Teva's Copaxone), most of which are approved broadly for the treatment of relapsing forms of MS. This category encompasses relapsing-remitting MS (RR-MS) and SP-MS patients who continue to experience relapses. Interviewed thought leaders suggest that, based on data in RR-MS, Genzyme/Sanofi/Bayer HealthCare's Lemtrada may offer advantages over sales-leading Copaxone on measures of physical disability—potentially translating into clinical benefits for SP-MS patients. 

"The neurologists we surveyed indicate that an improved effect on physical disability is one of the greatest unmet needs in SP-MS," said Decision Resources Analyst Georgiana L. Kuhlmann , S.M. "Drawing on clinical data from RR-MS trials, interviewed thought leaders indicate that Lemtrada has demonstrated the potential to partially fulfill this unmet need."

According to the DecisionBase 2013 report entitled On What Attributes Will Neurologists and Payers Differentiate Novel Therapies for Secondary-Pro
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
2. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
3. Biodels Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
4. Marken Acquires European Kit Building Operation From LabCorp Clinical Trials
5. Blood Disorders: European Hematologists Gather in Amsterdam, June 14-17, 2012
6. Mylan Launches Generic Lipitor® in Five European Countries
7. European Thrombosis Therapeutics Market is Experiencing an Urgent Need for Enhanced Products, Says Frost & Sullivan
8. Bristol-Myers Squibb to Present New Data on ORENCIA(R)? (abatacept) at the European League Against Rheumatism (EULAR) 2012 Congress
9. Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion
10. Study Results of Novocures NovoTTF™ Pivotal Phase 3 Trial Published in European Journal of Cancer
11. Cardiac Dimensions® Announces Publication of TITAN Clinical Trial Data in European Journal of Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ... stock of Solta Medical, Inc. (NASDAQ: SLTM ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... report is available in its catalogue: ... and Technologies for Advanced Drug Delivery ... Administration http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/15/2014)... Ohio , Jan. 15, 2014  A novel wearable injector ... easy and painless for patients to self-inject prescription drugs in ... disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to grow to $220B by 2018, according to analysts.   Many ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... Investment in Vaccine to Prevent Rotavirus, NEW ... that it has purchased a royalty interest in ... an oral,vaccine developed to prevent rotavirus infection, a ... infants and young children.,The product is marketed by ...
... The Public Patent,Foundation ("PUBPAT") announced today that the U.S. ... patents held by Gilead Sciences,that relate to the drug ... in the battle against HIV/AIDS. Gilead markets TDF in,the ... a part of its ATRIPLA,combination product., Roughly 40 ...
Cached Medicine Technology:Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKline's Rotarix(R) 2U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences' Claims 2
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
(Date:4/17/2014)... School of Medicine (BUSM) have discovered that the ... experimental model. The findings, reported in the ... may lead to more effective treatments for alcoholism. ... the leading causes of illness and death in ... by limiting the productivity of workers and necessitating ...
(Date:4/17/2014)... scientists and their partners have found that their proprietary ... transmission of multiple sexually transmitted infections (STIs) in both ... virus 2 (HSV-2), and human papillomavirus (HPV). The USAID-funded ... is effective against multiple strains of HIV, and has ... three viruses of at least eight hours prior to ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... , SUNDAY, Dec. 26 (HealthDay News) -- How do ... living human being and not a replica such as a doll ... they are crucial to helping people distinguish real faces from those ... face and knowing that the lights are on and someone is ...
... FRIDAY, Dec. 24 (HealthDay News) -- The lack of sleep ... put their health at risk, British sleep experts suggest. ... harm Santa,s long-term health, there are short-term risks, according to ... of Warwick,s Warwick Medical School. The lack of sleep ...
... , THURSDAY, Dec. 23 (HealthDay News) -- Eating ... toxic phosphorus in the blood and urine, says a small ... intake of phosphorous -- which is found in dietary proteins ... have difficulty ridding themselves of the mineral. In these patients, ...
... activated in cancers, causes internal membranes within a healthy ... degrading proteins, preventing the enzyme from doing its job ... cell, researchers at UCLA,s Jonsson Comprehensive Cancer Center have ... enzyme, Glycogen Synthase Kinase 3 (GSK3), results in the ...
... Reporter , WEDNESDAY, Dec. 22 (HealthDay News) -- Confronting ... who are unaware they are taking dummy pills, researchers ... was fake still reported significant symptom relief. In ... (IBS), a control group received no treatment while the ...
... THURSDAY, Dec. 23 (HealthDay News) -- Liz Smith has six kids, ... of arthritis in Emily, now 18, appeared when she was just ... slipped in a swimming pool and had a swollen ankle that ... all of it." For several months, the family agonized over ...
Cached Medicine News:Health News:Could Santa's Lack of Sleep on Christmas Eve Harm His Health? 2Health News:Vegetarian Diet Cuts Kidney Patients' Levels of Toxic Phosphorus 2Health News:UCLA researchers uncover new cell biological mechanism that regulates protein stability in cells 2Health News:Placebos Work -- Even if Patients Are in on the Secret 2Health News:Placebos Work -- Even if Patients Are in on the Secret 3Health News:Lifetime of Arthritis Has Not Held Back Teen 2Health News:Lifetime of Arthritis Has Not Held Back Teen 3
The Guidant INSIGNIA Ultra pacing system offers sophisticated patient-specific, easy-to-use features for simplified patient management and enhanced patient safety....
... fast, the HI VISION 8500 diagnostic ... with user-oriented operation for exceptional imaging ... package consists of advanced techniques for ... COMPOUND multi-angle spatial compounding, wideband pulse-inversion, ...
... range of diagnosis by using the Convex Scanning ... clear image of blood flow by using the ... accessory elevator has been incorporated and the balloon ... for more advanced and accurate techniques. The FG-36UX ...
... system is an expanded menu profiler designed ... much as 50 percent and deliver faster ... the AccuSense® glucose oxygen sensor, enhanced data ... the CX9 ALX system offers general and ...
Medicine Products: